1. Home
  2. CHAC vs ALT Comparison

CHAC vs ALT Comparison

Compare CHAC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHAC
  • ALT
  • Stock Information
  • Founded
  • CHAC 2025
  • ALT 1997
  • Country
  • CHAC United States
  • ALT United States
  • Employees
  • CHAC N/A
  • ALT N/A
  • Industry
  • CHAC
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHAC
  • ALT Health Care
  • Exchange
  • CHAC NYSE
  • ALT Nasdaq
  • Market Cap
  • CHAC 300.0M
  • ALT 339.0M
  • IPO Year
  • CHAC 2025
  • ALT N/A
  • Fundamental
  • Price
  • CHAC $10.10
  • ALT $3.61
  • Analyst Decision
  • CHAC
  • ALT Strong Buy
  • Analyst Count
  • CHAC 0
  • ALT 6
  • Target Price
  • CHAC N/A
  • ALT $18.20
  • AVG Volume (30 Days)
  • CHAC 457.0
  • ALT 3.7M
  • Earning Date
  • CHAC 01-01-0001
  • ALT 08-07-2025
  • Dividend Yield
  • CHAC N/A
  • ALT N/A
  • EPS Growth
  • CHAC N/A
  • ALT N/A
  • EPS
  • CHAC N/A
  • ALT N/A
  • Revenue
  • CHAC N/A
  • ALT $20,000.00
  • Revenue This Year
  • CHAC N/A
  • ALT N/A
  • Revenue Next Year
  • CHAC N/A
  • ALT $507,435.66
  • P/E Ratio
  • CHAC N/A
  • ALT N/A
  • Revenue Growth
  • CHAC N/A
  • ALT N/A
  • 52 Week Low
  • CHAC $9.98
  • ALT $2.90
  • 52 Week High
  • CHAC $11.28
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • CHAC N/A
  • ALT 34.55
  • Support Level
  • CHAC N/A
  • ALT $3.58
  • Resistance Level
  • CHAC N/A
  • ALT $4.39
  • Average True Range (ATR)
  • CHAC 0.00
  • ALT 0.20
  • MACD
  • CHAC 0.00
  • ALT -0.00
  • Stochastic Oscillator
  • CHAC 0.00
  • ALT 3.70

About CHAC CRANE HBR ACQUISITION CORP

Crane Harbor Acquisition Corp is a blank check company.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: